Biotech

Eurofins Discovery Announces Formation of its New Scientific Advisory Board

2022-05-24 23:00 955

SAN DIEGO, May 24, 2022 /PRNewswire/ -- Eurofins Discovery, the leading brand with over 35 years of success providing a complete solution of products and services for drug discovery, today announced the formation of its new Scientific Advisory Board (SAB). Company officials gathered renowned lead...

Nanoform 1Q 2022 report: Quarterly record of new projects and new customers

2022-05-24 14:16 861

HELSINKI, May 24, 2022 /PRNewswire/ -- The positive momentum continues. A quarterly record of eight new non-GMP projects with seven different customers signed. Revenue grew by 174%, the number of employees by 49%, while the total operating costs grew by 27%. The gross margin rose to 92%. Signific...

RemeGen to Present Three Studies on Disitamab Vedotin at 2022 ASCO Annual Meeting

2022-05-24 10:27 1053

YANTAI, China, May 23, 2022  /PRNewswire/ -- RemeGen Co., Ltd. (9995.HK, SHA: 688331), a commercial-stage biotechnology company, today announced that three abstracts for disitamab vedotin (RC48) have been selected for poster discussions by the 2022 American Society of Clinical Oncology (ASCO) Ann...

Biocytogen/Eucure Biopharma to Present Clinical Data from YH003 (anti-CD40 mAb) and YH001 (anti-CTLA-4 mAb) Trials at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

2022-05-24 08:00 1233

BEIJING, May 24, 2022 /PRNewswire/ -- Eucure Biopharma, a wholly owned subsidiary of Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen"), today announced that it will present two posters at the 2022 ASCO Annual Meeting, taking place inChicago, IL and virtually from June 3-7, 2022. The ...

Medison Pharma Announces Extension of Multi-territorial Agreement with Immunocore and Expansion into Australia and New Zealand

2022-05-23 20:28 2076

The latest geographic growth increases Medison's global footprint across 25 countries in four continents, further strengthening its commercial offering PETACH TIKVAH, Israel, May 23, 2022 /PRNewswire/ -- Medison Pharma ("Medison"), a global pharma company focused ...

CBC Welcomes Former Allergan CEO Brent Saunders to Join Hugel Board as Executive Chair

2022-05-20 15:00 1187

* Saunders brings decades of healthcare leadership experience, and plans to propel Korea's #1 medical aesthetics company into a global industry leader * Saunders will serve as Hugel's Executive Board Chair starting June 29, 2022 * The appointment of Saunders is an example of CBC Group continu...

HAVAS HEALTH & YOU APPOINTS DAN RUBIN AS PRESIDENT OF HAVAS HEALTH +

2022-05-19 21:15 1574

Key Senior Hire Will Partner with Allison Ceraso, President and CCO, Bolstering Agency Leadership Amongst Continued Network Momentum NEW YORK, May 19, 2022 /PRNewswire/ -- To continue to support health and wellness companies' rapidly expanding cultural relevance and dominance of global content, ...

CellCarta expands it proteomics portfolio with the acquisition of next-generation immuno-MRM assays from Precision Assays

2022-05-19 20:30 617

This acquisition solidifies CellCarta's leadership position in proteomics serviceswith a unique combination of validated set of reagents and multiplex assays, including pathway specific off-the-shelf panels, allowing for clinical protein quantification covering a comprehensive range of immuno-onc...

Gracell Biotechnologies to Participate in Three Upcoming Investor Conferences

2022-05-19 22:39 1853

SAN DIEGO, Calif., SUZHOU and SHANGHAI, China, May 19, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the treatment of can...

I-Mab to Hold Investor Call to Report Latest Phase 2 Clinical Data of its Differentiated CD73 Antibody Uliledlimab

2022-05-19 20:00 1099

SHANGHAI and GAITHERSBURG, MD., May 19 , 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq" IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that it will hold a call with investors at 8 a.m. EST on...

PolyU's Pioneering Technologies in AI, Materials Science and Biotechnology Awarded at TechConnect 2022 Innovation Awards

2022-05-19 19:50 1393

HONG KONG, May 19, 2022 /PRNewswire/ -- The Hong Kong Polytechnic University (PolyU) has won three prestigious global Innovation Awards in the areas of artificial intelligence (AI), materials science and biotechnology at the TechConnect World Innovation Conference and Expo 2022 (TechConnect) – th...

PostEra spearheads AI-driven drug discovery collaboration to develop antiviral therapeutics with initial $68M in NIH funding

2022-05-19 04:56 1593

BOSTON, May 19, 2022 /PRNewswire/ -- PostEra, a biotechnology company specializing in machine learning for preclinical drug discovery, today announced a multi-year collaboration with the National Institutes of Health to develop small molecule antiviral therapeutics to prevent pandemics. The cente...

Ascentage Pharma Announces Preclinical Data Demonstrating Olverembatinib's Therapeutic Potential in Treating COVID-19 Published in EMBO Molecular Medicine

2022-05-18 22:06 1563

SUZHOU, China and ROCKVILLE, Md., May 18, 2022 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that a new preclinical study, conducted by the rese...

Beyond Ventures Congratulates Prenetics on its Successful NASDAQ Listing

2022-05-18 21:45 1708

Prenetics is Beyond Ventures' Second Unicorn IPO from its Fund I Portfolio HONG KONG, May 18, 2022 /PRNewswire/ -- Hong Kong-based venture capital firm Beyond Ventures' first portfolio company Prenetics, aHong Kong unicorn and a global leader in genomic and diagnostic testing, listed on NASDAQ to...

BioVaxys Confirms First Clinical Site and Principal Investigators for Ovarian Cancer Vaccine Trial and Enters into Second Tumor Cell Supply Agreement

2022-05-18 20:00 2791

VANCOUVER, BC, May 18, 2022 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV; FRA: 5LB; OTCQB:BVAXF) ("BioVaxys" or "Company"), announced today that Hospices Civils deLyon, France ("HCL") has agreed to serve as a clinical study site for the Phase I study of BVX-0918, the Company's autologous ...

Laekna Therapeutics Raises $61 Million in Series D financing

2022-05-18 20:00 1128

SHANGHAI and WARREN, N.J., May 18, 2022 /PRNewswire/ -- Laekna Therapeutics (" Laekna"), a clinical-stage global biotechnology company dedicated to developing next generation medicines to treat cancer and liver diseases, announced that it has raised$61 million in Series D financing led by CS Capit...

DelSiTech and Anticancer Bioscience Announce a Collaboration Agreement for the Development of Long-acting Therapies in Oncology

2022-05-18 16:00 1320

TURKU, Finland, May 18, 2022 /PRNewswire/ -- DelSiTech Ltd, the leading silica drug delivery technology company, based inFinland and Anticancer Bioscience Ltd., an innovativeChina-base and international company pioneers in synthetic lethal approaches to precision oncology, today announced a notab...

KAZIA MARKS DIPG AWARENESS DAY; NEW PRECLINICAL DATA IN DIPG TO BE PRESENTED AT ISPNO CONFERENCE

2022-05-17 20:00 894

SYDNEY, May 17, 2022 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), a late-stage, oncology-focused drug development company, marks 'DIPG Awareness Day' by recognizing the tireless work of global researchers in this disease, and by calling for an increased focus on childhood ...

Exyte remains on record-level growth path in the first quarter of 2022 allowing for an uplifted year-end outlook

2022-05-17 17:00 1055

* Order intake doubled year-on-year, marking a new Q1-record with €2.6 billion * Sales increased strongly by more than a third to €1.5 billion, also reaching an all-time-high in Q1 * Adjusted EBITDA and Adjusted EBIT both increased over-proportionately to €105 million and €95 million, respect...

ABL AND ODIMMA THERAPEUTICS JOIN FORCES IN PERSONALIZED CANCER IMMUNOTHERAPY

2022-05-17 15:00 1056

PARIS, May 17, 2022 /PRNewswire/ -- ABL Europe (ABL ), a pure play contract development and manufacturing organization (CDMO) specialized in development and manufacturing of virus for vaccine candidates, gene and cancer therapies and Odimma Therapeutics (Od...

12345 ... 58